Suchergebnisse - "Gupta, Neeraj"

PubPharm (30)

1

Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma : Exposure-Response Analysis of the TOURMALINE-MM4 Study

enthalten in: Clinical pharmacology and therapeutics | 2023

von Srimani, J. | Diderichsen, P. | Hanley, M. | +2

2

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Srimani, J. | Diderichsen, P. | Hanley, M. | +3

3

Clinical Pharmacology of Ixazomib : The First Oral Proteasome Inhibitor

enthalten in: Clinical pharmacokinetics | 2019

von Gupta, N. | Hanley, M. | Xia, C. | +3

4

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma

enthalten in: British journal of haematology | 2019

von Kumar, S. | Grzasko, N. | Delimpasi, S. | +9

5

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

enthalten in: Clinical pharmacology and therapeutics | 2019

von Gupta, N. | Hanley, M. | Diderichsen, P. | +9

6

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

enthalten in: European journal of cancer (Oxford, England : 1990) | 2019

von Dimopoulos, M. | Grosicki, S. | Jędrzejczak, W. | +10

7

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3) : a double-blind, randomised, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Dimopoulos, M. | Gay, F. | Schjesvold, F. | +124

CommentIn: Lancet. 2019 Jan 19;393(10168):204-205. - PMID 30545778

8

Biotransformation of [14C]-ixazomib in patients with advanced solid tumors : characterization of metabolite profiles in plasma, urine, and feces

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Pusalkar, S. | Plesescu, M. | Gupta, N. | +6

9

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

enthalten in: Haematologica | 2018

von San-Miguel, J. | Echeveste Gutierrez, M. | Špicka, I. | +13

10

Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma

enthalten in: British journal of haematology | 2018

von Richardson, P. | Hofmeister, C. | Rosenbaum, C. | +15